Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US and EU approval for St Jude's non-rechargeable neurostimulator

This article was originally published in Clinica

Executive Summary

St Jude Medical has launched its EonC neurostimulator in the US following FDA premarket approval (PMA) for the treatment of chronic pain. The St Paul, Minnesota firm also CE marked the product for sale in Europe, and will launch it there next week. EonC delivers mild electrical pulses to the spinal cord, interrupting or masking pain signals. It is non-rechargeable, unlike St Jude's Eon and Eon Mini devices, which can be charged in a similar way to a mobile phone. St Jude said that EonC was designed for patients who do not want to be burdened with recharging, and claims it has the greatest battery capacity of any primary cell neurostimulator.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041710

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel